CA Patent

CA3217538A1 — New formulation

Assigned to MedinCell SA · Expires 2022-11-03 · 4y expired

What this patent protects

The present invention generally relates to an injectable formulation for sustained release of etonogestrel, a pharmaceutical dosage and an application device comprising such formulation, methods for preparing thereof, and use thereof for contraception.

USPTO Abstract

The present invention generally relates to an injectable formulation for sustained release of etonogestrel, a pharmaceutical dosage and an application device comprising such formulation, methods for preparing thereof, and use thereof for contraception.

Drugs covered by this patent

Patent Metadata

Patent number
CA3217538A1
Jurisdiction
CA
Classification
—
Expires
2022-11-03
Drug substance claim
No
Drug product claim
No
Assignee
MedinCell SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.